Senseonics Appoints Francine R. Kaufman, M.D. as Chief Medical Officer


Senseonics, maker of the Eversense and Eversense XL, announced the appointment of Francine R. Kaufman, M.D. as the company’s chief medical officer in a statement last week. Dr. Kaufman previously served as the president of the American Diabetes Association and the chief medical officer and vice president of Global Regulatory, Clinical and Medical Affairs at Medtronic Diabetes. She has spent nearly 40 years working in diabetes care.

Kaufman told Beyond Type 1 that she is “excited about the innovation that Senseonics has to offer people with diabetes. Not only is the methodology used to measure interstitial glucose truly novel, but the subcutaneous insertion is a true game changer.  I like the team, their commitment and their pipeline for the future. I felt this was simply a great fit.”

Kaufman is a Distinguished Professor Emerita of Pediatrics and Communications at the Keck School of Medicine and the Annenberg School of Communications at the University of Southern California. She is an attending physician at Children’s Hospital of Los Angeles, and was recognized by the California State Senate for her work in banning sodas in LA Unified School District (2004) and appointed by Congress as a Local Legend with the American Woman’s Medical Association.

Of the appointment, Senseonics President and CEO Tim Goodnow said, “Fran is one of the world’s leading endocrinologists and her deep understanding of the global medical, research and clinical diabetes community coupled with her track record of applying novel technologies to advance diabetes care for patients make her ideally suited for the role. We are confident that with her leadership, we will further transform and elevate the Eversense platform and bolster our US commercialization efforts at this critical point.” 

The Eversense and Eversense XL Continuous Glucose Monitors (CGMs) include a small sensor inserted under the skin that relays to a smart transmitter that sits on top of the sensor. The Eversense is FDA-approved for usage for up to 90 days.

“I think giving endocrinologists a procedure that is simple and enables people with diabetes to better manage their diabetes is truly exciting. The accuracy, the ease of use and the flexibility that Eversense offers are truly unique,” said Kaufman. “I think the future of CGM is implantable devices. It is easier for the patient to not have to change sensors. A longer sensor duration will make this such a viable choice for people. The future is to continue to provide accuracy, convenience, flexibility—with continued hardware and software improvements.”

Editorial Disclosure: Francine R. Kaufman, M.D. is a member of Beyond Type 1’s Science Advisory Council. Additionally, Senseonics is the Worldwide Presenting Sponsor of Type One Run, a program of Beyond Type 1.

This content mentions Medtronic, an active partner of Beyond Type 1.
News coverage by the Beyond Type 1 team is operated independently from any content partnerships. Beyond Type 1 maintains full editorial control of all content published on our platforms.

WRITTEN BY Beyond Type 1 Editorial Team, POSTED 03/14/19, UPDATED 11/07/22

This piece was authored collaboratively by the Beyond Type 1 Editorial Team. Members of that team include Editorial Manager Todd Boudreaux, Program Manager Mariana Gómez, Director of Brand Communications Dana Howe and Editorial Associate Jordan Dakin.